NCT00576823 - Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

October 31, 2009

Conditions

HydronephrosisNeurogenic Bladder

Interventions

DRUG

Alfuzosin

"Dose: 0.2 mg/kg/day~Route: oral"

Trial Locations (12)

Sanofi-Aventis Administrative Office, Sofia

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Tallinn

Sanofi-Aventis Administrative Office, Mumbai

Sanofi-Aventis Administrative Office, Kuala Lumpur

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Belgrade

Sanofi-Aventis Aministrative Office, Singapore

Sanofi-Aventis Administrative Office, Bratislava

Sanofi-Aventis Administrative Office, Taipei

Sanofi-Aventis Administrative Office, Istanbul